143 related articles for article (PubMed ID: 27294106)
1. Integration of HIV in the Human Genome: Which Sites Are Preferential? A Genetic and Statistical Assessment.
Gonçalves J; Moreira E; Sequeira IJ; Rodrigues AS; Rueff J; Brás A
Int J Genomics; 2016; 2016():2168590. PubMed ID: 27294106
[TBL] [Abstract][Full Text] [Related]
2. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.
Mitchell RS; Beitzel BF; Schroder AR; Shinn P; Chen H; Berry CC; Ecker JR; Bushman FD
PLoS Biol; 2004 Aug; 2(8):E234. PubMed ID: 15314653
[TBL] [Abstract][Full Text] [Related]
3. Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma.
Ferber MJ; Thorland EC; Brink AA; Rapp AK; Phillips LA; McGovern R; Gostout BS; Cheung TH; Chung TK; Fu WY; Smith DI
Oncogene; 2003 Oct; 22(46):7233-42. PubMed ID: 14562053
[TBL] [Abstract][Full Text] [Related]
4. Retroviral DNA integration: viral and cellular determinants of target-site selection.
Lewinski MK; Yamashita M; Emerman M; Ciuffi A; Marshall H; Crawford G; Collins F; Shinn P; Leipzig J; Hannenhalli S; Berry CC; Ecker JR; Bushman FD
PLoS Pathog; 2006 Jun; 2(6):e60. PubMed ID: 16789841
[TBL] [Abstract][Full Text] [Related]
5. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
6. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites.
Wilke CM; Hall BK; Hoge A; Paradee W; Smith DI; Glover TW
Hum Mol Genet; 1996 Feb; 5(2):187-95. PubMed ID: 8824874
[TBL] [Abstract][Full Text] [Related]
7. Preferential integration of a transfected marker gene into spontaneously expressed fragile sites of a breast cancer cell line.
Matzner I; Savelyeva L; Schwab M
Cancer Lett; 2003 Jan; 189(2):207-19. PubMed ID: 12490314
[TBL] [Abstract][Full Text] [Related]
8. Transcription start regions in the human genome are favored targets for MLV integration.
Wu X; Li Y; Crise B; Burgess SM
Science; 2003 Jun; 300(5626):1749-51. PubMed ID: 12805549
[TBL] [Abstract][Full Text] [Related]
9. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells.
Hematti P; Hong BK; Ferguson C; Adler R; Hanawa H; Sellers S; Holt IE; Eckfeldt CE; Sharma Y; Schmidt M; von Kalle C; Persons DA; Billings EM; Verfaillie CM; Nienhuis AW; Wolfsberg TG; Dunbar CE; Calmels B
PLoS Biol; 2004 Dec; 2(12):e423. PubMed ID: 15550989
[TBL] [Abstract][Full Text] [Related]
10. Prospects for gene therapy using HIV-based vectors.
Yee JK; Zaia JA
Somat Cell Mol Genet; 2001 Nov; 26(1-6):159-74. PubMed ID: 12465467
[TBL] [Abstract][Full Text] [Related]
11. Proviruses with Long-Term Stable Expression Accumulate in Transcriptionally Active Chromatin Close to the Gene Regulatory Elements: Comparison of ASLV-, HIV- and MLV-Derived Vectors.
Miklík D; Šenigl F; Hejnar J
Viruses; 2018 Mar; 10(3):. PubMed ID: 29517993
[TBL] [Abstract][Full Text] [Related]
12. Viral integration, fragile sites, and proto-oncogenes in human neoplasia.
Popescu NC; Zimonjic D; DiPaolo JA
Hum Genet; 1990 Apr; 84(5):383-6. PubMed ID: 2323772
[TBL] [Abstract][Full Text] [Related]
13. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses.
Derse D; Crise B; Li Y; Princler G; Lum N; Stewart C; McGrath CF; Hughes SH; Munroe DJ; Wu X
J Virol; 2007 Jun; 81(12):6731-41. PubMed ID: 17409138
[TBL] [Abstract][Full Text] [Related]
14. Preferential integration of marker DNA into the chromosomal fragile site at 3p14: an approach to cloning fragile sites.
Rassool FV; McKeithan TW; Neilly ME; van Melle E; Espinosa R; Le Beau MM
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6657-61. PubMed ID: 1862089
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.
Lewinski MK; Bisgrove D; Shinn P; Chen H; Hoffmann C; Hannenhalli S; Verdin E; Berry CC; Ecker JR; Bushman FD
J Virol; 2005 Jun; 79(11):6610-9. PubMed ID: 15890899
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells.
Beard BC; Dickerson D; Beebe K; Gooch C; Fletcher J; Okbinoglu T; Miller DG; Jacobs MA; Kaul R; Kiem HP; Trobridge GD
Mol Ther; 2007 Jul; 15(7):1356-65. PubMed ID: 17440443
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in cancer as a result of breakage at fragile sites.
Popescu NC
Cancer Lett; 2003 Mar; 192(1):1-17. PubMed ID: 12637148
[TBL] [Abstract][Full Text] [Related]
18. Pinpointing recurrent proviral integration sites in new models for latent HIV-1 infection.
Lange UC; Bialek JK; Walther T; Hauber J
Virus Res; 2018 Apr; 249():69-75. PubMed ID: 29550509
[TBL] [Abstract][Full Text] [Related]
19. Viral determinants of integration site preferences of simian immunodeficiency virus-based vectors.
Monse H; Laufs S; Kuate S; Zeller WJ; Fruehauf S; Uberla K
J Virol; 2006 Aug; 80(16):8145-50. PubMed ID: 16873270
[TBL] [Abstract][Full Text] [Related]
20. HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness.
Badaracco G; Venuti A; Sedati A; Marcante ML
J Med Virol; 2002 Aug; 67(4):574-82. PubMed ID: 12116007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
